Roper Technologies $ROP

Recent News (15)

• Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD) GlobeNewswire · 28 Aug 2026 Basel, 28 August 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-ret…
• Roche’s US subsidiary Genentech announces manufacturing expansion in the United States GlobeNewswire · 20 Aug 2026 Basel, 20 August 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY) today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facilit…
• What Are Wall Street Analysts' Target Price for Roper Technologies Stock? Yahoo Finance · 20 Aug 2026 What Are Wall Street Analysts' Target Price for Roper Technologies Stock?
• Analyst Report: Roper Technologies Inc Yahoo Finance · 06 Aug 2026 Analyst Report: Roper Technologies Inc
• Roper Technologies to present at Oppenheimer Technology Conference GlobeNewswire · 04 Aug 2026 SARASOTA, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Oppenheimer 29th Annual Technology, Internet & Communications Conferen…
• CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) GlobeNewswire · 24 Jul 2026 Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susv…
• Roper Technologies Q2 Earnings Call Highlights Yahoo Finance · 23 Jul 2026 Roper Technologies Q2 Earnings Call Highlights
• Earnings call transcript: Roper Technologies tops Q2 2026 estimates, lifts outlook Investing.com · 23 Jul 2026 Earnings call transcript: Roper Technologies tops Q2 2026 estimates, lifts outlook
• Roper Technologies announces second quarter financial results GlobeNewswire · 23 Jul 2026 Increases full year guidance Increases full year guidance
• [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc GlobeNewswire · 23 Jul 2026 Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single …
• ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now? The Globe and Mail · 20 Jul 2026 ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now?  The Globe and Mail
• ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now? The Globe and Mail · 20 Jul 2026 ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now?  The Globe and Mail
• ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now? TradingView · 20 Jul 2026 ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now?  TradingView
• ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now? Zacks Investment Research · 20 Jul 2026 ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now?  Zacks Investment Research
• ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now? Yahoo Finance · 20 Jul 2026 ACN or ROP: Which IT Services Stock Should Grace Your Portfolio Now?  Yahoo Finance